

Xiaoping Hou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/559655/publications.pdf>

Version: 2024-02-01

14
papers

201
citations

1478505

6
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

249
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9703-9723.	6.4	45
2	Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1770-1785.	6.4	42
3	Regioselective Epoxide Ring Opening for the Stereospecific Scale-Up Synthesis of BMS-960, A Potent and Selective Isoxazole-Containing S1P ₁ Receptor Agonist. <i>Organic Process Research and Development</i> , 2017, 21, 200-207.	2.7	25
4	Discovery of Highly Potent Liver X Receptor $\hat{1}^2$ Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1207-1212.	2.8	21
5	Synthesis of ethyl 3-phenyl-4-(trifluoromethyl)isoxazole-5-carboxylate via regioselective dipolar cycloaddition. <i>Tetrahedron Letters</i> , 2012, 53, 3994-3997.	1.4	15
6	An Efficient Scale-Up Synthesis of BMS-520, a Potent and Selective Isoxazole-Containing S1P ₁ Receptor Agonist. <i>Organic Process Research and Development</i> , 2016, 20, 989-995.	2.7	15
7	A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist. <i>Journal of Organic Chemistry</i> , 2021, 86, 8851-8861.	3.2	7
8	Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14773-14792.	6.4	7
9	Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2195-2203.	2.8	6
10	Large-scale supercritical fluid chromatography purification of unstable STING agonist intermediates. <i>Journal of Chromatography A</i> , 2021, 1651, 462309.	3.7	5
11	Development of a Rapid Scale-Up Synthesis of (S)-N-(8-((2-Amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide, a Potent Adaptor-Associated Kinase 1 Inhibitor. <i>Organic Process Research and Development</i> , 0, , .	2.7	4
12	Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272. <i>Organic Process Research and Development</i> , 2022, 26, 1327-1335.	2.7	4
13	The effect of water on the large-scale supercritical fluid chromatography purification of two factor XIa active pharmaceutical ingredients. <i>Journal of Chromatography A</i> , 2021, 1651, 462318.	3.7	3
14	Long-Acting Tumor-Activated Prodrug of a TGF $\hat{1}^2$ R Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15787-15798.	6.4	2